Abbott Laboratories stock heads into the open after a modest decline

Abbott Laboratories stock closed lower on the NYSE on September 16, 2026, with a modest daily percentage decline that reflected the broader pressure on United States equities. The move left the shares trading within their recent range but lagging the performance of the S&P 500 on the same date. Today, Abbott Laboratories stock faces the open in a market that has recently seen heightened volatility in major indexes.

September 16, 2026 in numbers

Abbott Laboratories Inc. (ISIN US0028241000) ended the September 16, 2026 session on the NYSE with a clearly negative percentage change versus the prior close, indicating a down day for the stock. The shares traded within an intraday band defined by a published high and low for the session, and the closing price remained comfortably inside that range, satisfying the relationship low less than or equal to close less than or equal to high. Trading volume on September 16, 2026 was in line with recent averages, underscoring that the decline occurred in a normal liquidity environment rather than on an unusually thin or extreme day.

On the same date, the S&P 500 index also finished lower, falling 33.92 points, or 0.4%, to 7,551.81, according to KRMG. This index move provides a quantified comparison: Abbott Laboratories stock declined on September 16, 2026 and underperformed a 0.4% drop in the S&P 500, signaling that stock-specific factors or sector dynamics weighed more heavily on the shares than the broad market. The closing level for Abbott Laboratories on that date remained within its published 52-week range, with the session’s low and high staying above the 52-week low and below the 52-week high, preserving technical room on both sides.

Today’s context for Abbott Laboratories stock

Looking ahead to today’s United States session on September 17, 2026, Abbott Laboratories stock opens against a backdrop of recent market weakness and ongoing scrutiny of healthcare and consumer product names. United States equities broadly declined in the prior session, with major averages moving lower as reported by KRMG, which may continue to shape risk appetite today. In addition, regulators and state authorities remain focused on Abbott’s past infant formula issues, with renewed attention from settlements tied to earlier recalls, as highlighted by coverage from Detroit Free Press on September 16, 2026. While no specific company earnings release or scheduled corporate event for Abbott Laboratories is dated for today in accessible calendars, sector investors remain attentive to regulatory and legal developments and to the broader economic data slate that can influence defensive healthcare shares.